Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

04 déc. 2025 07h00 HE | Source: MapLight Therapeutics, Inc.

MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress

Topline results from Phase 2 ZEPHYR trial of ML-007C-MA for schizophrenia expected in the second half of 2026Topline results from Phase 2 VISTA trial of ML-007C-MA for Alzheimer’s disease psychosis...
29 oct. 2025 09h06 HE | Source: MapLight Therapeutics, Inc.

MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares

SAN FRANCISCO and BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from...
26 oct. 2025 17h30 HE | Source: MapLight Therapeutics, Inc.

MapLight Therapeutics Announces Pricing of Initial Public Offering

SAN FRANCISCO and BOSTON, Oct. 26, 2025 (GLOBE NEWSWIRE) -- MapLight Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients suffering from...